TCR²'s ga­vo-cel sur­vives a PhI test. Now it's head-first in­to PhII with a half-dozen par­tial re­spons­es

A T cell biotech has some pos­i­tive re­sults, and now that the da­ta are out, the biotech is mov­ing for­ward on its next steps.

TCR² Ther­a­peu­tics teased re­sults from the Phase I por­tion of an on­go­ing Phase I/II study Tues­day, go­ing on a con­fer­ence call Wednes­day to dive more in­to the de­tails of what end­ed up hap­pen­ing. The com­pa­ny’s drug can­di­date, ga­vo-cel, is be­ing in­ves­ti­gat­ed in sol­id tu­mors ex­press­ing mesothe­lin, a pro­tein that has been ex­am­ined as a bio­mark­er in oth­er T cell ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER